


R^6 is selected from -H and $-C_1-C_8$ alkyl;

R^7 is selected from -H, $-C_1-C_8$ alkyl, $-C_3-C_8$ carbocycle, $-O-(C_1-C_8$ alkyl), -aryl, $-C_1-C_8$ alkyl-aryl, $-C_1-C_8$ alkyl- $(C_3-C_8$ carbocycle), $-C_3-C_8$ heterocycle and $-C_1-C_8$ alkyl- $(C_3-C_8$ heterocycle);

5 each R^8 is independently selected from -H, -OH, $-C_1-C_8$ alkyl, $-C_3-C_8$ carbocycle and $-O-(C_1-C_8$ alkyl);

R^9 is selected from -H and $-C_1-C_8$ alkyl;

R^{10} is selected from



10 Z is -O-, -S-, -NH- or $-N(R^{14})$ -;

R^{11} is selected from -H, -OH, $-NH_2$, $-NHR^{14}$, $-N(R^{14})_2$, $-C_1-C_8$ alkyl, $-C_3-C_8$ carbocycle, $-O-(C_1-C_8$ alkyl), -aryl, $-C_1-C_8$ alkyl-aryl, $-C_1-C_8$ alkyl- $(C_3-C_8$ carbocycle), $-C_3-C_8$ heterocycle and $-C_1-C_8$ alkyl- $(C_3-C_8$ heterocycle); or R^{11} is an oxygen atom which forms a carbonyl unit ($C=O$) with the carbon atom to which it is attached and a hydrogen atom on

15 this carbon atom is replaced by one of the bonds in the ($C=O$) double bond;


each R^{12} is independently selected from -aryl and $-C_3-C_8$ heterocycle;

R^{13} is selected from -H, -OH, $-NH_2$, $-NHR^{14}$, $-N(R^{14})_2$, $-C_1-C_8$ alkyl, $-C_3-C_8$ carbocycle, $-O-(C_1-C_8$ alkyl), -aryl, $-C_1-C_8$ alkyl-aryl, $-C_1-C_8$ alkyl- $(C_3-C_8$ carbocycle), $-C_3-C_8$ heterocycle and $-C_1-C_8$ alkyl- $(C_3-C_8$ heterocycle); and

20 Each R^{14} is independently -H or $-C_1-C_8$ alkyl.


2. The compound of claim 1 wherein w is an integer ranging from 2 to 12.

3. A compound of the formula Ib:



or a pharmaceutically acceptable salt or solvate thereof

RECEIVED BY
ATTORNEY



Z is -O-, -S-, -NH- or -N(R¹⁴)-;


R¹¹ is selected from -H, -OH, -NH₂, -NHR¹⁴, -N(R¹⁴)₂, -C₁-C₈ alkyl, -C₃-C₈ carbocycle, -O-(C₁-C₈ alkyl), -aryl, -C₁-C₈ alkyl-aryl, -C₁-C₈ alkyl-(C₃-C₈ carbocycle), -C₃-C₈ heterocycle and -C₁-C₈ alkyl-(C₃-C₈ heterocycle); or R¹¹ is an oxygen atom which forms a carbonyl unit (C=O) with the carbon atom to which it is attached and a hydrogen atom on this carbon atom is replaced by one of the bonds in the (C=O) double bond;

each R¹² is independently selected from -aryl and -C₃-C₈ heterocycle;

R¹³ is selected from -H, -OH, -NH₂, -NHR¹⁴, -N(R¹⁴)₂, -C₁-C₈ alkyl, -C₃-C₈ carbocycle, -O-(C₁-C₈ alkoxy), -aryl, -C₁-C₈ alkyl-aryl, -C₁-C₈ alkyl-(C₃-C₈ carbocycle), C₃-C₈ heterocycle and -C₁-C₈ alkyl-(C₃-C₈ heterocycle); and
each R¹⁴ is independently -H or -C₁-C₈ alkyl.

6. The compound of claim 5 wherein w is an integer ranging from 2 to 12.

7. A compound or a pharmaceutically acceptable salt or solvate of the compound of claim 1 where -D is a Drug unit having the structure



or a pharmaceutically acceptable salt or solvate thereof,

wherein, independently at each location:

R² is selected from -H and -methyl;

R³ is selected from -H, -methyl, and -isopropyl;


R⁴ is selected from -H and -methyl; R⁵ is selected from -isopropyl, -isobutyl, -sec-butyl, -methyl and -t-butyl or R⁴ and R⁵ join, have the formula - (CR^aR^b)_n- where R^a and R^b are independently selected from -H, -C₁-C₈ alkyl, and -C₃-C₈ carbocycle, and n is

selected from 2, 3, 4, 5 and 6, and form a ring with the carbon atom to which they are attached;

R^6 is selected from -H and -methyl;

each R^8 is independently selected from -OH, -methoxy and -ethoxy;

5 R^{10} is selected from




R^{24} is selected from H and $-C(O)R^{25}$; wherein R^{25} is selected from $-C_1-C_8$ alkyl, $-C_3-C_8$ carbocycle, -aryl, $-C_1-C_8$ alkyl-aryl, $-C_1-C_8$ alkyl- (C_3-C_8) carbocycle, $-C_3-C_8$ heterocycle and $-C_1-C_8$ alkyl- (C_3-C_8) heterocycle);

10 Z is -O-, -NH-, $-OC(O)-$, $-NHC(O)-$, $-NR^{28}C(O)-$; where R^{28} is selected from -H and $-C_1-C_8$ alkyl;

n is 0 or 1; and

R^{27} is selected from -H, $-N_3$, $-C_1-C_8$ alkyl, $-C_3-C_8$ carbocycle, -aryl, $-C_1-C_8$ alkyl-aryl, $-C_1-C_8$ alkyl- (C_3-C_8) carbocycle, $-C_3-C_8$ heterocycle and $-C_1-C_8$ alkyl- (C_3-C_8) heterocycle) when n is 0; and R^{27} is selected from -H, $-C_1-C_8$ alkyl, $-C_3-C_8$ carbocycle, -aryl, $-C_1-C_8$ alkyl-aryl, $-C_1-C_8$ alkyl- (C_3-C_8) carbocycle, $-C_3-C_8$ heterocycle and $-C_1-C_8$ alkyl- (C_3-C_8) heterocycle) when n is 1.

8. A compound or a pharmaceutically acceptable salt or solvate of the compound of claim 1 where -D is a Drug unit having the structure




20

9. A compound or a pharmaceutically acceptable salt or solvate of the compound of claim 1 where -D is a Drug unit having the structure


or a pharmaceutically acceptable salt or solvate thereof.

90. A compound having the structure



or a pharmaceutically acceptable salt or solvate thereof.

5 91. A compound having the structure



or a pharmaceutically acceptable salt or solvate thereof.

92. The compound or a pharmaceutically acceptable salt or solvate thereof of any one of claims 1, 3, 5, 32, 34, 35, 36, 37, 38, 43 or 44, in an isolated or a purified form.